Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial

Blood 2026

View at publisher
Authors: A. S. Robertz, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa Veronika Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Christian Peter Jaworek
+7 more Michael Fuchs, Carsten Kobe, Christian Baues, P Borchmann, Bastian von Tresckow, Karolin Behringer, Paul J Bröckelmann
DOI: 10.1182/blood.2025031809
Cited by: 1
References: 21

Abstract

ABSTRACT: In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4×N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Cancer Risks and Factors Reproductive Biology and Fertility

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
25
Pages
3118–3121
Publication date
2 April 2026
Language
EN